Abstract 1529
Background
Elevated AFP in patients (pts) with HCC is associated with worse prognosis. Two placebo (P)-controlled trials (REACH, REACH-2) have studied ramucirumab (RAM, anti-VEGFR2 antibody) in pts with HCC after sorafenib, with REACH-2 enrolling only pts with baseline AFP ≥400 ng/mL. In REACH-2 RAM treatment (trt) improved overall survival (OS) compared to P, consistent with REACH (AFP ≥400 ng/mL) pts. Here we present post-hoc analyses assessing the prognostic and predictive value of baseline AFP in both studies.
Methods
Pts with HCC, Child-Pugh A, ECOG PS 0-1, and prior sorafenib were randomized to RAM 8 mg/kg or P Q2W. The prognostic value of baseline AFP was assessed by Cox regression models with either continuous or dichotomous (≥400 vs < 400 ng/ml) AFP (REACH, N = 565), and confirmed using Cox model with continuous AFP ≥400 ng/mL (REACH-2, N = 292). Cox model with AFP and its trt interaction assessed the predictive value of baseline AFP in REACH. Subpopulation trt effect pattern plot (STEPP) assessed the interaction between RAM trt and AFP in REACH, REACH-2 and pooled individual pt data analysis of both studies (AFP ≥400 mg/mL).
Results
Baseline AFP was confirmed as a significant continuous (REACH and REACH-2; p<.0001) and dichotomous (REACH; p<.01) prognostic factor for OS. AFP remained the predominant prognostic factor after adjusting for other significant prognostic factors, including macrovascular invasion and ECOG PS. The interaction between AFP and trt effect was significant in REACH (p=.0042 continuous; p<.0001 dichotomous), suggesting the predictive value of AFP in RAM OS benefit. Based on Cox regression of OS on continuous AFP level and its interaction with trt, the estimated OS hazard ratio in REACH (<0.8, 95% CI below 1) was significant at each AFP value ≥400 ng/mL, supporting AFP ≥400 ng/mL as selection criterion for RAM OS benefit. STEPP supported these results with OS benefits at each AFP value ≥400 ng/mL.
Conclusions
The prognostic impact of baseline AFP is an important factor to consider in trial design. The findings suggest AFP may be predictive of RAM OS benefit. Results also confirm AFP ≥400 ng/mL is appropriate selection criterion for RAM OS benefit.
Clinical trial identification
NCT01140347, NCT02435433.
Editorial acknowledgement
Nathalie Godinot, funded by Eli Lilly and Company.
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
A.X. Zhu: Advisory / Consultancy: Eisai; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Exelixis; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly and Company; Advisory / Consultancy: Roche/Genentech. P.R. Galle: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bayer Schering Pharma; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sirtex Medical; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Eli Lilly and Company; Honoraria (self), Advisory / Consultancy: Bristol-Meyers Squibb; Advisory / Consultancy: MSD; Honoraria (self): Sillajen. J.M. Llovet: Advisory / Consultancy: Eli Lilly and Company; Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy: Celsion; Advisory / Consultancy: Incyte; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Glycotest; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): Bayer Schering Pharma. R.S. Finn: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche Genentech; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy: Exelixis. Y. Kang: Advisory / Consultancy: Eli Lilly and Company; Advisory / Consultancy: Taiho Pharmaceutical; Advisory / Consultancy: Ono Pharmaceutical; Advisory / Consultancy: Roche Genentech; Advisory / Consultancy: Merck Serono; Advisory / Consultancy, Research grant / Funding (self): DAE HWA Pharmaceutical; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Astellas Pharma; Advisory / Consultancy, Research grant / Funding (self): LSK Biopharma. E. Assenat: Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Terasphere; Honoraria (self), Advisory / Consultancy: Sirtex Medical; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Servier. G. Brandi: Advisory / Consultancy: Eli Lilly and Company. K. Motomura: Honoraria (self): Eisai. I. Ohno: Advisory / Consultancy: Merck Serono; Speaker Bureau / Expert testimony: Taiho Pharmaceutical. B. Daniele: Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai; Honoraria (self): Eli Lilly; Honoraria (self), Advisory / Consultancy: Ipsen; Advisory / Consultancy: Incyte; Advisory / Consultancy: MSD; Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Celgene. A. Vogel: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy: Delcath Systems; Honoraria (self), Advisory / Consultancy: Eli Lilly and Company; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy: Baxalta; Travel / Accommodation / Expenses: Ipsen; Honoraria (self): Sanofi; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): MSD. T. Yamashita: Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Eisai. C. Hsu: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Advisory / Consultancy: Eli Lilly and Company; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Merck Serono; Honoraria (self), Travel / Accommodation / Expenses: Merck Sharp & Dohme; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Taiho Pharmaceutical. T. Meyer: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Eisai; Advisory / Consultancy, Research grant / Funding (institution): Ipsen; Advisory / Consultancy: Tarveda Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): BTG; Advisory / Consultancy: Beigene; Advisory / Consultancy: MSD; Research grant / Funding (institution): Bayer. R. Widau: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. W. Schelman: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. C. Wang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. Y. Hsu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. M. Kudo: Honoraria (self), Advisory / Consultancy: MSD; Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Research grant / Funding (institution): AbbVie; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self): Gilead Sciences; Honoraria (self): Otsuka; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy: EA Pharma; Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Otsuka; Research grant / Funding (institution): Bristol-Myers Squibb Japan. All other authors have declared no conflicts of interest.
Resources from the same session
3330 - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
Presenter: Leonora De Boo
Session: Poster Display session 2
Resources:
Abstract
3971 - Unravelling the biological characteristics of MammaPrint extreme risk subgroups
Presenter: Rajith Bhaskaran
Session: Poster Display session 2
Resources:
Abstract
5871 - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes
Presenter: Catalina Falo
Session: Poster Display session 2
Resources:
Abstract
5014 - Clinical validation of CanAssist Breast in a Spanish cohort
Presenter: Manjiri Bakre
Session: Poster Display session 2
Resources:
Abstract
2787 - Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer
Presenter: Peter A. Fasching
Session: Poster Display session 2
Resources:
Abstract
4301 - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
Presenter: Gaia Griguolo
Session: Poster Display session 2
Resources:
Abstract
3205 - Frequency of germline mutations in women's cancer susceptibility genes in a large cohort of Chinese breast cancer patients
Presenter: Ning Liao
Session: Poster Display session 2
Resources:
Abstract
4091 - Triple blinded Prospective Study assessing the Impact of Genomics & Artificial Intelligence Watson For Oncology (WFO) on MDT’s Decision of Adjuvant Systemic Therapy for Hormone Receptor Positive Early Breast Carcinoma-
Presenter: Somashekhar Sampige Prasannakumar
Session: Poster Display session 2
Resources:
Abstract
4359 - Prognostic significance of Progesterone Receptor levels in luminal-like Her2- early Breast Cancer patients. A retrospective single Cancer Center analysis.
Presenter: Anna Diana
Session: Poster Display session 2
Resources:
Abstract
1369 - PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis
Presenter: Francesco Schettini
Session: Poster Display session 2
Resources:
Abstract